• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by LeMaitre Vascular Inc.

    1/22/24 9:58:21 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care
    Get the next $LMAT alert in real time by email
    SC 13G 1 lemaitre_sc13g.htm SC 13G

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. ______)*

     

    LEMAITRE VASCULAR INC
    (Name of Issuer)
     
    Common Stock
    (Title of Class of Securities)
     
    525558201
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      x Rule 13d-1(b)

     

      o Rule 13d-1(c)

     

      o Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    SCHEDULE 13G

     

    CUSIP No. 525558201
     
    1  

    Names of Reporting Persons

     

    Copeland Capital Management, LLC

    2  

    Check the appropriate box if a member of a Group (see instructions)

     

    (a)  o

    (b)  o

     

    3  

    Sec Use Only

     

    4  

    Citizenship or Place of Organization

     

    State of Delaware, United States

    Number of
    Shares
      Beneficially   
    Owned by
    Each
    Reporting
    Person
    With:
      5   

    Sole Voting Power

     

    892,607

      6   

    Shared Voting Power

     

    94,937

      7   

    Sole Dispositive Power

     

     

      8   

    Shared Dispositive Power

     

    1,259,961

    9  

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    1,259,961

    10  

    Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

     

    o

    11  

    Percent of class represented by amount in row (9)

     

    5.7%

    12  

    Type of Reporting Person (See Instructions)

     

    IA

    Page 2 of 5 

     

    Item 1.  

     

    (a) Name of Issuer: LEMAITRE VASCULAR INC

     

    (b) Address of Issuer’s Principal Executive Offices: 63 Second Avenue Burlington, Massachusetts

     

    Item 2.    

     

    (a) Name of Person Filing: Sofia A. Rosala

     

    (b) Address of Principal Business Office or, if None, Residence: 161 Washington St, Suite 1325, Conshohocken, PA 19428

     

    (c) Citizenship: U.S.A

     

    (d) Title and Class of Securities: Common Stock

     

    (e) CUSIP No.: 525558201

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) o Broker or dealer registered under Section 15 of the Act;
         
    (b) o Bank as defined in Section 3(a)(6) of the Act;
         
    (c) o Insurance company as defined in Section 3(a)(19) of the Act;
         
    (d) o Investment company registered under Section 8 of the Investment Company Act of 1940;
         
    (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
         
    (f) o An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
         
    (g) o A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
         
    (h) o A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) o A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
         
    (j) o A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
         
    (k) o Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

    Page 3 of 5 

     

    Item 4. Ownership

     

    (a) Amount Beneficially Owned: 1,259,961

     

    (b) Percent of Class: 5.7%

     

    (c) Number of shares as to which such person has:

     

      (i) Sole power to vote or to direct the vote: 892,607
         
      (ii) Shared power to vote or to direct the vote: 189,875

     

      (iii) Sole power to dispose or to direct the disposition of: 1,259,961
         
      (iv) Shared power to dispose or to direct the disposition of:

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following o.

     

    Item 6. Ownership of more than Five Percent on Behalf of Another Person.

     

    Item 7.

    Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.

     

    Item 8.

    Identification and classification of members of the group.

     

    Item 9.

    Notice of Dissolution of Group.

     

    Item 10. Certifications.

    Page 4 of 5 

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

       
    Dated: January 19, 2024
       
    /s/ Signature    (-s- Sofia A. Rosala)
    Name/Title  Sofia A. Rosala, General Counsel and CCO

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).

    Page 5 of 5 

    Get the next $LMAT alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LMAT

    DatePrice TargetRatingAnalyst
    8/6/2025$95.00Mkt Perform → Outperform
    Barrington Research
    2/28/2025Outperform → Perform
    Oppenheimer
    2/28/2025Outperform → Mkt Perform
    Barrington Research
    2/13/2025$95.00Equal Weight
    Wells Fargo
    10/15/2024$96.00Neutral
    Cantor Fitzgerald
    8/2/2024$85.00 → $105.00Buy
    Lake Street
    5/31/2024$100.00Buy
    ROTH MKM
    4/26/2024$59.00 → $75.00Hold → Buy
    Stifel
    More analyst ratings

    $LMAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Jasinski Lawrence J sold $90,553 worth of shares (976 units at $92.78), decreasing direct ownership by 17% to 4,773 units (SEC Form 4)

    4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)

    8/14/25 4:30:07 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    President and Director Roberts David B exercised 10,815 shares at a strike of $37.27 and sold $999,173 worth of shares (10,815 units at $92.39) (SEC Form 4)

    4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)

    8/13/25 5:08:21 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    Director Ross Bridget A exercised 2,500 shares at a strike of $37.29 and sold $235,000 worth of shares (2,500 units at $94.00) (SEC Form 4)

    4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)

    8/13/25 8:55:24 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    $LMAT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LeMaitre Q2 2025 Financial Results

    BURLINGTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q2 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q2 2025: Sales $64.2mm, +15% (+15% organic)Gross margin 70.0%, +110 bpsOp. income $16.1mm, +12%Op. margin 25%Earnings per diluted share $0.60, +16%Cash up $16.9mm sequentially to $319.5mm Catheters (+27%) and grafts (+19%) drove Q2 sales growth. EMEA sales increased 23%, Americas 12%, and APAC 12%. Price accounted for 8% of sales growth and units 7%. Gross margin of 70.0% (vs. 68.9% in Q2 2024) increased due to higher average selling prices

    8/5/25 4:05:16 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    LeMaitre Will Announce Second Quarter 2025 Earnings Results August 5, 2025

    BURLINGTON, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at ir.lemaitre.com. About LeMaitre LeMaitre is a provider of devices, implants, and services fo

    7/8/25 4:04:39 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

    MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. "On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company" commented John Seaberg, Chairman o

    6/9/25 10:52:06 PM ET
    $AVR
    $LMAT
    Industrial Specialties
    Health Care
    Medical/Dental Instruments

    $LMAT
    SEC Filings

    View All

    SEC Form 144 filed by LeMaitre Vascular Inc.

    144 - LEMAITRE VASCULAR INC (0001158895) (Subject)

    8/8/25 4:22:15 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by LeMaitre Vascular Inc.

    10-Q - LEMAITRE VASCULAR INC (0001158895) (Filer)

    8/6/25 6:06:10 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    LeMaitre Vascular Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - LEMAITRE VASCULAR INC (0001158895) (Filer)

    8/5/25 4:22:59 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    $LMAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lemaitre Vascular upgraded by Barrington Research with a new price target

    Barrington Research upgraded Lemaitre Vascular from Mkt Perform to Outperform and set a new price target of $95.00

    8/6/25 7:37:02 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    Lemaitre Vascular downgraded by Oppenheimer

    Oppenheimer downgraded Lemaitre Vascular from Outperform to Perform

    2/28/25 8:28:09 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    Lemaitre Vascular downgraded by Barrington Research

    Barrington Research downgraded Lemaitre Vascular from Outperform to Mkt Perform

    2/28/25 7:39:54 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    $LMAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by LeMaitre Vascular Inc.

    SC 13G - LEMAITRE VASCULAR INC (0001158895) (Subject)

    10/22/24 3:49:21 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by LeMaitre Vascular Inc. (Amendment)

    SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)

    2/13/24 5:08:02 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by LeMaitre Vascular Inc. (Amendment)

    SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)

    2/12/24 3:02:21 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    $LMAT
    Financials

    Live finance-specific insights

    View All

    LeMaitre Q2 2025 Financial Results

    BURLINGTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q2 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q2 2025: Sales $64.2mm, +15% (+15% organic)Gross margin 70.0%, +110 bpsOp. income $16.1mm, +12%Op. margin 25%Earnings per diluted share $0.60, +16%Cash up $16.9mm sequentially to $319.5mm Catheters (+27%) and grafts (+19%) drove Q2 sales growth. EMEA sales increased 23%, Americas 12%, and APAC 12%. Price accounted for 8% of sales growth and units 7%. Gross margin of 70.0% (vs. 68.9% in Q2 2024) increased due to higher average selling prices

    8/5/25 4:05:16 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    LeMaitre Will Announce Second Quarter 2025 Earnings Results August 5, 2025

    BURLINGTON, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at ir.lemaitre.com. About LeMaitre LeMaitre is a provider of devices, implants, and services fo

    7/8/25 4:04:39 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    LeMaitre Q1 2025 Financial Results

    BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q1 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q1 2025: Sales $59.9mm, +12% (+13% organic)Gross margin 69.2%, +60 bpsOp. income $12.6mm, +6%Op. margin 21%Earnings per diluted share $0.48, +10%Cash up $2.8mm sequentially to $302.5mm Grafts (+17%) and carotid shunts (+14%) drove sales growth. EMEA sales increased 18%, Americas 11%, and APAC 3%. Gross margin was 69.2% (vs. 68.6% in Q1 2024), due to higher average selling prices and manufacturing efficiencies. Operating income of $12.6mm wa

    5/1/25 4:05:32 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    $LMAT
    Leadership Updates

    Live Leadership Updates

    View All

    Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

    MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. "On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company" commented John Seaberg, Chairman o

    6/9/25 10:52:06 PM ET
    $AVR
    $LMAT
    Industrial Specialties
    Health Care
    Medical/Dental Instruments

    Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors

    GARDNER, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Joseph P. "JJ" Pellegrino, Jr. to its Board of Directors. Mr. Pellegrino, who will also serve as Chairman of the Board's Audit Committee, brings decades of operational and financial experience as well as an extensive knowledge of the medical device industry to the board. Mr. Pellegrino most recently served as Chief Financial Officer of LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of devices, implants and services for the treatm

    3/20/25 9:00:00 AM ET
    $LMAT
    $POCI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Former Johnson & Johnson Executive Joins Advisory Board at Maitri Health Technologies

    Bridget Ross brings extensive experience in MedTech development and services;Joins advisory board of healthcare, logistics, capital markets and innovation leaders VANCOUVER, BC, March 23, 2021 /PRNewswire/ - Maitri Health Technologies Corp. ("Maitri") (CSE: MTEC) (FRA: D84), a global platform for healthcare supply security, today announced the appointment of Bridget Ross to its Advisory Board. Ms. Ross is currently CEO of ChroniSense Medical, Ltd., an Israel-based MedTech company and maker of wearable, medical-grade disease management devices. Ms. Ross serves as a Board Director for LeMaitre Vascular Inc. (NASDAQ: LMAT) and as a mentor for early stage MedTech companies through MassMEDIC and

    3/23/21 8:00:00 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care